The Valley Desk

ArticleFuture oncology (London, England)Published

Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source

Publication record

Type
Article
Venue
Future oncology (London, England)
Published
Subject terms
Humans; Prognosis; Retrospective Studies; Female; Triple Negative Breast Neoplasms; Progression-Free Survival; Erb-b2 Receptor Tyrosine Kinases; Retrospective Study; Overall Survival; Triple Negative Breast Cancer; Real-world Data; Real-world Progression-free Survival
PubMed ID
37191097
Added to directory
Source checked

Report a correction or request removal